| Literature DB >> 30674710 |
Jinjin Zhang1, Qian Chen1, Dingfu Du1, Tong Wu1, Jingyi Wen1, Meng Wu1, Yan Zhang1, Wei Yan1, Su Zhou1, Yan Li1, Yan Jin1, Aiyue Luo1, Shixuan Wang1.
Abstract
Aging has been regarded as a treatable condition, and delaying aging could prevent some diseases. Ovarian aging, a special type of organ senescence, is the earliest-aging organ, as ovaries exhibit an accelerated rate of aging with characteristics of gradual declines in ovarian follicle quantity and quality since birth, compared to other organs. Ovarian aging is considered as the pacemaker of female body aging, which drives the aging of multiple organs of the body. Hence, anti-ovarian aging has become a research topic broadly interesting to both biomedical scientists and pharmaceutical industry. A marked progress has been made in exploration of possible anti-ovarian agents or approaches, such as calorie restriction mimetics, antioxidants, autophagy inducers etc., over the past years. This review is attempted to discuss recent advances in the area of anti-ovarian aging pharmacology and to offer new insights into our better understanding of molecular mechanisms underlying ovarian aging, which might be informative for future prevention and treatment of ovarian aging and its related diseases.Entities:
Keywords: organ senescence; ovarian aging; pacemaker; pharmacological strategies
Year: 2019 PMID: 30674710 PMCID: PMC6366956 DOI: 10.18632/aging.101784
Source DB: PubMed Journal: Aging (Albany NY) ISSN: 1945-4589 Impact factor: 5.682
Figure 1Classification of anti-ovarian aging drugs. Some drugs may have several pharmacological actions.